The Superior Therapeutic Properties of SOM230 Originate from Unique Structural Elements


  • Ian Lewis
  • Gisbert Weckbecker
  • Herbert A. Schmid
  • Steven W.J. Lamberts
  • Viktor Boerlin
  • Joost van der Hoek
  • Günter Bovermann
  • Lukas Oberer
  • Janos Pless
  • Nagarajan Chandramouli
  • Wilfried Bauer
  • Rainer Albert
  • Christian Bruns



Cyclohexapeptide template, Solid phase synthesis, Srif analogue, Superior therapeutic properties


A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high affinity binding to human somatostatin receptors (sst1-5). SOM230 has potent, long lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase II clinical trials.




How to Cite

I. Lewis, G. Weckbecker, H. A. Schmid, S. W. Lamberts, V. Boerlin, J. van der Hoek, G. Bovermann, L. Oberer, J. Pless, N. Chandramouli, W. Bauer, R. Albert, C. Bruns, Chimia 2004, 58, 222, DOI: 10.2533/000942904777677902.